{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:08:32Z","timestamp":1791950912128,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS16\/01433"],"award-info":[{"award-number":["FIS16\/01433"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["BDNS357800"],"award-info":[{"award-number":["BDNS357800"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.bbmt.2019.01.012","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T17:36:36Z","timestamp":1547141796000},"page":"1022-1030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"25","author":[{"given":"Beatriz","family":"Guglieri-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Perez-Pitarch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garcia-Cadenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Rabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Hernandez-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valcarcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Esquirol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Ferriols-Lisart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-0817","authenticated-orcid":false,"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Pi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.01.012_bib0001","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/TP.0b013e31824810e6","article-title":"Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients","volume":"93","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0002","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0003","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0004","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.transproceed.2008.03.084","article-title":"Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials","volume":"40","author":"Demopoulos","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","article-title":"Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis","volume":"110","author":"Marty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0006","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbmt.2003.12.305","article-title":"Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation","volume":"10","author":"Cutler","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0007","doi-asserted-by":"crossref","first-page":"e12717","DOI":"10.1111\/tid.12717","article-title":"Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients","volume":"19","author":"Solano","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0008","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3324\/haematol.2016.149294","article-title":"A prospective randomized trial comparing cyclosporine\/methotrexate and tacrolimus\/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"T\u00f6rl\u00e9n","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0009","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0010","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3324\/haematol.2012.065599","article-title":"The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate","volume":"98","author":"Perez-Sim\u00f3n","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0011","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1111\/ajt.14754","article-title":"Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Pi\u00f1ana","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0012","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.bbmt.2017.03.035","article-title":"A time-to-event model for acute kidney injury after reduced-intensity conditioning stem cell transplantation using a tacrolimus- and sirolimus-based graft-versus-host disease prophylaxis","volume":"23","author":"Pi\u00f1ana","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0013","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.clinbiochem.2009.06.018","article-title":"Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer","volume":"42","author":"Schmid","year":"2009","journal-title":"Clin Biochem"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0014","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/JCM.02571-13","article-title":"Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value?","volume":"52","author":"Gim\u00e9nez","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0015","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/bmt.2015.303","article-title":"Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood","volume":"51","author":"Solano","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0016","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0017","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0018","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0019","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0020","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0021","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0022","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0023","series-title":"NONMEM User's Guide","author":"Beal","year":"1989"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0024","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1128\/JVI.78.20.11030-11039.2004","article-title":"Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase","volume":"78","author":"Kudchodkar","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0025","doi-asserted-by":"crossref","first-page":"14182","DOI":"10.1073\/pnas.0605825103","article-title":"Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes","volume":"103","author":"Kudchodkar","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0026","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1128\/JVI.02733-09","article-title":"Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication","volume":"84","author":"Moorman","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0027","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1600-6143.2012.04002.x","article-title":"CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages","volume":"12","author":"Poglitsch","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0028","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chom.2008.03.002","article-title":"Human cytomegalovirus protein UL38 inhibits host cell stress responses by antagonizing the tuberous sclerosis protein complex","volume":"3","author":"Moorman","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0029","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1128\/JVI.02124-06","article-title":"Human cytomegalovirus UL38 protein blocks apoptosis","volume":"81","author":"Terhune","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0030","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0031","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0032","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0033","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0034","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1517\/14740338.2016.1132698","article-title":"Safety of mTOR inhibitors in adult solid organ transplantation","volume":"15","author":"Ventura-Aguiar","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0035","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood.V96.8.2703.h8002703_2703_2711","article-title":"Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation","volume":"96","author":"Thomson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0036","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2002-12-3629","article-title":"Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen","volume":"102","author":"Mohty","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0037","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","article-title":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","volume":"157","author":"Chou","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bbmt.2019.01.012_bib0038","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2009.25.0654","article-title":"Basic concepts and methods for joint models of longitudinal and survival data","volume":"28","author":"Ibrahim","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119300278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119300278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:06:49Z","timestamp":1761059209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119300278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1083879119300278"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}